Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling